Recent research highlights the potential of ectopically expressed LMP1 in tumor B cells to prime autologous CD4+ T-cells (LMP1-CD4+ T) against a wide array of endogenous tumor antigens, including TAAs and neoantigens, suggesting efficient treatment for B cell malignancies [132]. This evidence concerns the gene PDLIM7 and neoplasm.